Psoriatic Arthritis
391
48
71
231
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
102 trials with published results (26%)
Research Maturity
231 completed trials (59% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
5.1%
20 terminated out of 391 trials
92.0%
+5.5% vs benchmark
25%
97 trials in Phase 3/4
44%
102 of 231 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 231 completed trials
Clinical Trials (391)
A Study of SPY072 in Rheumatic Disease
CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
Deployment o the Multidisciplinary Prospective Cohort Imminent
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Employment and Arthritis: Making it Work
Modifying PEST for Psoriatic Arthritis Screening
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis